


QIAGEN and global Ebola surveillance



QIAGEN has a strong track record and long-standing experience in surveillance of infectious disease outbreaks. Being a trusted partner of many national and international healthcare authorities worldwide, QIAGEN made significant contributions to fight previous pandemic threats, providing the first assays for [SARS](#) and leading offerings for the [swine flu](#) and [bird flu](#) outbreaks. Likewise, the company has initiated various activities in order to support the containment of the current Ebola outbreak, which currently poses a significant threat to West Africa and the world.

QIAGEN has unique development, manufacturing and commercialization infrastructures as well as automation capabilities in place to ensure the global accessibility of Ebola test products within short periods of time.

All existing QIAGEN products to support Ebola testing are based on advanced molecular technologies which provide significant benefits over traditional testing methods. Real-time PCR based Ebola tests [were found](#) to be significantly more sensitive than other methods, enabling an earlier identification of acute infections and thus more effective patient management. Hence, leading health authorities such as the WHO consider real-time PCR to be the current [method of choice](#) for Ebola virus detection.

As a trusted partner, QIAGEN is now working with international organizations and research institutions in- and outside of Africa by providing testing components, tests and instruments for Ebola virus detection – both through commercial as well as corporate social responsibility activities. Our activities include:

- The Ebola Zaire (EZ1) rRT-PCR (TaqMan®) Assay test used by the [US Department of Defense](#) relies on RNA Extraction using the QIAamp® Viral RNA Mini Kit. It was the first test for diagnosing the Ebola Zaire virus detected in the West Africa outbreak to receive an FDA emergency use authorization, which was granted in August 2014.
- QIAGEN recently signed an agreement for commercialization of a highly sensitive, fully automated Ebola diagnosis/surveillance test with our Hamburg-based partner [altona Diagnostics](#) and for use on QIAGEN automation platforms. QIAGEN will now start making this test accessible through our commercial networks in many countries around the world, including in Africa.
- QIAGEN [supports a project initiated by the Broad Institute & Harvard University](#) in collaboration with the Kenema Government Hospital in Sierra Leone. Through donations of various consumable sample & assay technology products, we supported the setup of



QIAGEN Fact Sheet

local testing infrastructures in Africa and research projects which aim to get further insights into the virus.

- Our consumable products and instruments such as the QIAcube and the EZ1 Advanced are key solutions for numerous laboratories around the world in the research and diagnosis of Ebola.

Photo credits: CDC/ Frederick Murphy